Status:
COMPLETED
The Effect of Food Intake on the Pharmacokinetic of Single Dose SPH3127 Tablets in Chinese Health Subjects
Lead Sponsor:
Shanghai Pharmaceuticals Holding Co., Ltd
Conditions:
Hypertension
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
This study is a single-center, randomized, open, double-cycle and double-cross and self-reflection phase Ic clinical trial, to evaluate effect and safety of high fat diet on pharmacokinetics of SPH312...
Detailed Description
Participants who are in panel A will receive a single dose of a SPH3127 tablets 200mg when limosis, then fast 4h after dosing, and 72 hours later participants take the second dose of SPH3127 200mg aft...
Eligibility Criteria
Inclusion
- The body mass index is 19 \~ 26kg/m2 (including the critical value), which allows the minimum weight of male to be 50kg (including the critical value) and 45kg (the critical value) for women.
- Before the study, participants have kown about the significance, potential benefits, inconveniences and potential risks of the study and can follow the research's procedure and already sign the informed consent
Exclusion
- Participant who pregnancy, lactating women, and plan to get pregnant within six months after the clinical trial
- Participant who has significant abnormal physical examination, laboratory examination results (such as: liver function examination - aspartate aminotransferase (AST) and alanine aminotransferase (ALT) more than 1.5 times that of the upper limit of normal)
- Participant who has a history of cardiovascular, liver, kidney, digestive tract, nervous system, blood system, familial hematologic disease, abnormal thyroid function, or mental abnormality
- Participant who has drug allergy history, allergy constitution
- Participant who took oral contraceptives within 6 weeks
- Participant who used any drug (including Chinese herbal medicine) within 1 week
- Participant who donated blood within 2 months
- Participant who participated clinical trials of any drug in the past 3 months (as subjects)
- Participant who has any positive result of virus serology check : human immunodeficiency virus antigen antibody (HIV Ag/Ab) and hepatitis c virus (HCV) - Immunoglobulin G（IgG)antibody to IgG, hepatitis b surface antigen (HBsAg) and treponema pallidum antibody (TP)
- Participant who are smoking, drinking, drinking coffee, strong tea and drug abusers
- Participant who the researchers believe that there are volunteers who are not suitable for the study
Key Trial Info
Start Date :
September 23 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 30 2018
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT03249753
Start Date
September 23 2017
End Date
September 30 2018
Last Update
November 15 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The capital medical university affiliated Beijing anzhen hospital
Beijing, Beijing Municipality, China, 100029